Phosphoproteomics: A possible route to novel biomarkers of breast cancer

Proteomics - Clinical Applications

Volumn 2, Issue 2, 2008, Pages 181-194

  Metodiev, Metodi ^a   Alldridge, Louise ^b  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

Author keywords

Biomarkers; Breast cancer; Phosphoproteomics

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROLACTIN; PROTEIN 14 3 3; PROTEIN TYROSINE KINASE; SMAD2 PROTEIN; TAMOXIFEN; VASCULOTROPIN; VINCA ALKALOID;

ANGIOGENESIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER INHIBITION; CANCER RESEARCH; DISEASE MARKER; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; FUNCTIONAL PROTEOMICS; HORMONAL THERAPY; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REVIEW;

EID: 39649090531     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780011     Document Type: Review

References (128)

1. Hunter, D. J., Kraft, R, Jacobs, K. B., Cox, D. G. et al., A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 2007, 37, 870-874.
2. Broxterman, H. J., Lankelma, J., Hoeckman, K., Resistance to cytotoxic and anti-angiogenic agents: Similarities and differences. Drug Resist. Updat. 2003, 6, 111-127.
3. Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W. et al., The sequence of the Human genome. Science 2001, 291, 1304-1351.
4. Kononen, J., Bubendorf, L., Kallioniemi, A., Börland, M. et al., Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat. Med. 1998, 4, 844-847.
5. Petricoin, F., Bischel, V. E., Calvert, V. S., Espina, V. et al., Mapping molecular networks using proteomics: A vision for patient-tailored combination therapy. J. Clin. Oncol. 2005, 23, 3614-3621.
6. Rubinfeld, H., Seger, R., The ERK cascade: A prototype of MAPK signaling. Mol. Biotechnol. 2005, 31, 151-74.
7. Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H., Goldsmith, E. J., Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90, 859-869.
8. Prenzel, N., Zwick, E., Leserer, M., Ullrich, A., Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: Convergence point for signal integration and diversification. Breast Cancer Res. 2000, 2, 184-190.
9. Waksman, G., Crystal structure of the phosphotyrosine recognition domain SH2 of the Src oncogene product complexed with tyrosine-phosphorylated peptides. Cell Mol. Biol. (Noisy-le-grand) 1994, 40, 611-618.
10. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S. et al., Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498-2504.
11. Dolph, P. J., Ranganathan, R., Colley, N. J., Hardy, R. W. et al., Arrestin function in inactivation of G protein-coupled receptor rhodopsin in vivo. Science 1993, 260, 1910-1916.
12. Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G., Lefkowitz, R. J., beta-Arrestin: A protein that regulates beta-adrenergic receptor function. Science 1990, 248, 1547-1550.
13. DeFea, K. A., Stop that cell! Beta-arrestin-dependent chemotaxis: A tale of localized actin assembly and receptor desensitization. Annu. Rev. Physiol. 2007, 69, 535-560.
14. Karin, M., Ben-Neriah, Y., Phosphorylation meets ubiquitination: The control of NF-kappa B activity. Annu. Rev. Immunol. 2000, 8, 621-663.
15. Hanahan, D., Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100, 57-70.
16. Ueda, S., Tsuda, H., Sato, K., Takeuchi, H. et al., Alternative tyrosine phosphorylation of signalling kinases according to hormone receptor status in breast cancer over-expressing the insulin-like growth factor receptor type 1. Cancer Sci. 2006, 97, 597-604.
17. Schmitz, K. J., Grabellus, F., Cialles, R., Wohlsclaeger, J. et al., Relationship and prognostic significance of phosph-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression. Virchows Arch. 2006, 448, 16-23,
18. Xia, W., Chen, J. S., Zhou, X., Sun, P. R. et al., Phosphorylation/cytoplasmic localisation of p21Cip1/Waf1 is associated with HER2/neu over expression and provides a novel combination predictor for poor prognosis in breast cancer patients, Clin. Cancer Res. 2004, 11, 3815-3824.
19. Murphy, L., Dherlet, T., Adeyinka, A., Niu, Y. et al., Phosphserine 118 estrogen receptor-alpha detection in human breast tumours in vivo. Clin. Cancer Res. 2004, 10, 1354-1359.
20. Liapis, G., Mylona, E., Paraskevi, A., Giannopoulou, I., Effect of the different Smad2 protein localisations on the invasive breast phenotype. APMIS 2007, 115, 104-114.
21. Mansour, S. J., Matten, W. T., Herman, A. S., Candia, J. M. et al., Transformation of mammalian cells by constitutively active MAP Kinase kinase. Science 1994, 265, 965-970.
22. Roovers, K., Assoian, R. K., Integrating the MAPKinase signal into the G1 phase cell cycle machinery. Bioessays 2000, 22, 818-826.
23. Alldridge, L. C., Bryant, C. E., Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp. Cell Res. 2003, 290, 93-107.
24. Theodosiou, A., Ashworth, A., MAP kinase phosphatases. Genomebiology 2002, 3, 3009. 1-3009.10.
25. Milde-Langosch, K., Bamberger, A. M., Rieck, G., Grund, D. et al., Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br. J. Cancer 2005, 92, 2206-2215.
26. Davidson, B., Konstantinovsky, S., Kleinburg, L., Nguyen, M. T. R et al., The mitogen activated kinas p38 and JNK are markers for tumour progression in breast carcinoma. Gynecol. Oncol. 2006, 102, 453-461.
27. Gutzman, J. H., Nikolai, S. E., Rugowski, D. E., Watters, J. J., Schuler, L. A., Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: Role of ERK1/2-mediated signals to c-fos. Mol. Endocrinol. 2005, 19, 1765-1778.
28. Leslie, N. R., Downes, C. P., PTEN function: How normal cells control it and tumour cells lose it. Biochem. J. 2004, 382, 1-11.
29. Vivanco, I., Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501.
30. Perren, A., Weng, L. P., Boang, A. H., Ziebold, U. et al., Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 1999, 155, 1253-1260.
31. Chung, J. H., Ostrowski, M. C., Romigh, T., Minaguchi, T. et al., The ERK1/2 pathway modulates nuclear PTEN-mediated cell-cycle arrest by cyclin D1 transcriptional regulation. Hum. Mol. Genet. 2006, 15, 2553-2559.
32. Manavathi, B., Rayala, S., Rakesh, K., Phosphorylation dependent regulation of the stability and transforming potential of ETS transcription factor ESE-1 by p21-Activated Kinase 1. J. Biol. Chem. 2007, 282, 19820-19830,
33. Karas, R. H., Gauer, E. A., Bieber, H. E., Baur, W. E., Mendelsohn, M. E., Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen-activated protein kinase-independent pathway. J. Clin. Invest. 1998, 101, 2851-2861.
34. Bunone, G., Briand, P. A., Miksieck, R. J., Picarq, D., Activation of the unliganded estrogen receptor by EGF involves MAPkinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-2183.
35. Rogatsky, I., Trowbridge, J. M., Garabedian, M. J., Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclinA-CDK2 complex. J. Biol. Chem. 1999, 274, 22296-22302.
36. Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D. et al., PI3K/AKT mediated activation of estrogen receptor alpha: A new model for anti estrogen resistance. J. Biol. Chem. 2001, 276, 9817-9824.
37. Lannigan, D. A., Estrogen receptor phosphorylation. Steroids 2003, 68, 1-9.
38. Ma, Y., Hu, C., Riegel, A. T., Fan, S., Rosen, E., Growth factor signalling pathways modulate BRCA-1 repression of estrogen receptor-alpha activity. Mol. Endocrinol. 2007, 21, 1905-1923.
39. Wollmann, W., Goodman, M. L., Bhat-Nakshatri, P., Goulet, R. J. et al., Macrophage inhibitory cytokine integrates Akt/PKB and MAP kinase signalling pathways in breast cancer cells. Carcinogenesis 2005, 26, 900-907.
40. Vandermoere, F., Yazidi-Belkoura, I. E., Demon, Y., Slomainny, C. et al., The valosin-containing protein (VCP) is a target of Akt signalling required for cell survival. J. Biol. Chem. 2006, 281, 14307-14313.
41. Faivre, E. J., Lange, C. A., Progesterone receptors up-regulate Wnt-1 to induce epidermal growth factor receptor trans activation and src-dependent sustained activation of ERK1/2 MAPK in breast cancer cells. Mol. Cell. Biol. 2007, 27, 466-480.
42. Daniel, A. R., Qiu, M., Faivre, E. J., Ostrander, J. H. et al., Linkage of progestin and epidermal growth factor signalling: Phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids 2007, 72, 186-201.
43. Hondermarck, H., Breast cancer. When proteomics challenges biological complexity. Mol. Cell. Proteomics 2003, 2, 281-291.
44. Descamps, S., Toillon, R. A., Adriaenssens, E., Pawlowski, V. et al., Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signalling pathways. J. Biol. Chem. 2001, 276, 17864-17870.
45. Gschwind, A., Fischer, O. M., Ullrich, A., The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer 2004, 4, 361-370.
46. Srinivasan, R., Benton, E., McCormick, F., Thomas, H., Gullick, W. J., Expression of the C-ERB-3/HER-3 and C-ERB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 beta, and beta cellulin in normal endometrium cancer. Clin. Cancer Res. 1999, 5, 2877-2883.
47. Maatti, J. M., Sundvall, M., Juntilla, T., Peri, L., Proteolytic cleavage and phosphorylation of tumour associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol. Cell, Biol. 2006, 17, 67-79.
48. Derynck, R., Akhurst, R. J., Balmain, A., TGF-beta signalling in tumour suppression and cancer progression. Nat. Genet. 2001, 29, 117-129.
49. Souchelnytski, S., Transforming growth factor beta signalling and its role in cancer. Exp. Oncol. 2002, 24, 3-12.
50. Wilson, C. A., Cajulis, E. E., Green, J. L., Olsen, T. M. et al., HER-2 overexpression differentially alters transforming growth factor-Beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res. 2005, 7, 1056-1079.
51. Derynck, R., Akhurst, R. J., TGF beta signalling in cancer, a double edged sword. Trends Cell Biol. 2001, 11, S44-NaN.
52. Hagan, S., Al-Mulla, F., Mallon, E., Oien, K. et al., Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin. Cancer Res. 2005, 11, 7392-7397.
53. Yoon, S. O., Shin, S., Lipscomb, E. A., A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: The alpha 6beta4 integrin regulates Erb B2 translation and trans activates epidermal growth factor receptor/ErbB2 signalling. Cancer Res. 2006, 66, 2732-2739.
54. Vadlamudi, R. K., Sahin, A. A., Adam, L., Wang, R. A., Kumar, R., Heregulin and HER-2 signalling selectively activates c-src phosphorylation at tyrosine 215. FEBS Lett. 2003, 543, 76-80.
55. Schmitz, K. J., Grabellus, F., Cialles, R., Otterbach, F. et al., High expression of focal adhesion kinase(Pfak) in node negative breast cancer is related to overexpression of HER-2 and activated AKT but does not predict outcome. Breast Cancer Res. 2005, 7, 194-203.
56. Bretscher, A., Rapid phosphorylation and organisation of ezrin and spectrin accompany morphological changes induced in A-431 cells by EGF. J. Cell. Biol. 1989, 108, 921-930.
57. Matsui, T., Maeda, M., Doi, Y., Yonemura, S. et al., Rhokinase phosphorylates COOH-terminal threonines of ezrin/radoxin/moesin (ERM) proteins and regulates their head to tail association. J. Cell Biol, 1998, 140, 647-657.
58. Elliot, B. E., Quao, H., Louvard, D., Arpin, M., Cooperative effect of cSrc and ezrin in deregulation of cell-cell contacts and scattering of mammary carcinoma cells. J. Cell Biochem. 2004, 92, 16-28.
59. Srivastava, J., Elliot, B. E., Louvard, D., Arpin, M., Src-dependent ezrin phosphorylation in adhesion-mediated signalling. Mol. Biol. Cell 2005, 16, 1418-1490.
60. Torka, R., Thuma, F., Herzog, V., Kirfel, G., ROCK signalling mediates the adoption of different modes of migration and invasion in human mammary epithelial tumours. Exp. Cell. Res. 2006, 312, 3857-3871.
61. Bowden, E. T., Onikoyi, E. S., Slack, R., Myoui, A. et al., Colocalisation of cortactin and phosphotyrosine identifies activ invadopodia in human breast cancer cell lines. Exp. Cell. Res. 2006, 312, 1240-1253.
62. Cardone, R. A., Bagorda, A., Bellizzi, A., Busco, G. et al., Protein kinase A gating of a psuedopodial-located RhoA/ROCK/p38/NHE-1 signal module regulates invasion in breast cancer cell lines. Mol. Biol. Cell 2005, 16, 3117-3127.
63. Caceres, M., Guerrero, J., Martinez, J., Over expression of RhoA-GTP induces activation of the EGFR, dephosphorylation of FAK and increased motility in breast cancer cells. Exp. Cell. Res. 2005, 309, 229-238.
64. Rahmi, N., Hung, W., Tremblay, E., Saulnier, R., Elliot, B., cSrc kinase activity is required for hepatocyte growth factor-induced motility and anchorage independent growth of mammary carcinoma cells. J. Biol. Chem. 1998, 273, 33714-33721.
65. Nurcombe, V., Smart, C. E., Chipperfield, H., Cool, S. M. et al., The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparin sulfates. J. Biol. Chem. 2000, 275, 30009-30018.
66. Wang, E M., Lui, H. Q., Lui, S. R., Tang, S. P. et al., Shp-2 promoting migration and metastasis of MCF7 with loss of E-cadherin, dephophorylation of FAK and secretion of mmp-9 INDUCED BY il-1 beta in vivo and in vitro.Breast Cancer Res. 2005, 89, 5-14.
67. Vogel, W. F., Aszodi, A., Alves, F., Pawson, T., Discoidin- domain receptor-1 tyrosine kinase has ah essential role in mamrnary gland development. Mol. Cell Biol. 2001, 21, 2906-2917.
68. Hansen, C., Greengard, P., Nairn, A. C., Andersson, T., Vogel, W. F., Phosphorylation of DABPP-32 regulates breast cancer cell migration downstream of the receptor tyrosine kinase DDR-1. Exp. Cell Res. 2006, 312, 4011-4018.
69. Yamashita, H., Nishio, M., Kobayashi, S., Ando, Y., Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases post relapse survival in metastatic breast cancer. Breast Cancer Res. 2005, 7, 53-764.
70. Likhite, V. S., Stoss, F., Kim, K., Katzenellenbogen, B. S., Katzenellenbogen, J. A., Kinase specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 2006, 12, 3120-3132.
71. Felekkis, K. N., Narsimhan, R. P., Near, R., Castro, A. F. et al., AND-34 activates PI3K and induces anti-estrogen resistence in a SH2 and GDP exchange factor-like manner. Mol. Cancer Res. 2005, 3, 32-41.
72. Duan, L., Sturber, K., Kolomeichuk, S., Kim, H. et al., Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug induced apoptosis and senescence ar a step subsequent to mitotic arrest. Biochem. Pharmacol. 2007, 73, 481-490.
73. Mitra, S. K., Mikolon, D., Molina, J. E, Hsia, D. A. et al., Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumours. Oncogene 2006, 44, 5969-5984.
74. Wiseman, B. S., Werb, Z., The stromal effects on mammary gland development and breast cancer. Science 2002, 296, 160-184.
75. Blankenstein, T., The role of inflammation in tumour growth and tumour suppression. Novartis Found. Symp. 2004, 256, 6-21.
76. Iyengar, P., Espina, V., Williams, T. W., Lin, Y. et al., Adipocyte-derived collagen VI affects early mammary tumour progression in vivo, demonstrating a critical interaction in the tumour/stroma microenvironment. J. Clin. Invest. 2005, 115, 1163-1176.
77. Allinen, M., Beroukhim, R., Cai, L., Brennan, C. et al., Molecular characterisation of the tumour microenvironment in breast cancer. Cancer Cell 2004, 6, 17-32.
78. O'Neil, J. S., Miller, R. W., Aromatase activity in breast adipose tissue from women with benign and malignant breast disease. Br. J. Cancer 1997, 156, 601-604.
79. Yamanuchi, Y., Microenvironmental regulation of estrogen signals in breast cancer. Breast Cancer 2007, 14, 175-181.
80. Broxterman, H., Georgopapadakou, N. H., New cancer therapeutics: Target specific in, cytotoxics out. Drug Resist. Updat. 2004, 7, 79-87.
81. Guy, G. R., Philip, R., Tan, Y. H., Analysis of cellular phosphoproteins by two-dimensional gel electrophoresis: Applications for cell signaling in normal and cancer cells. Electrophoresis 1994, 15, 417-440.
82. Steinberg, T. H., Agnew, B. J., Gree, K. R., Leung, W. Y. et al., Global quantitative phosphoprotein analysis using Multiplexed Proteomics technology. Proteomics 2003, 3, 1128-1144.
83. Godovac-Zimmermann, J., Soskic, V., Poznanovic, S., Brianza, F., Functional proteomics of signal transduction by membrane receptors. Electrophoresis 1999, 20, 952-961.
84. Oda, Y., Nagasu, T., Chait, B. T., Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat, Biotechnol. 2001, 19, 379-382.
85. McLachlin, D. T., Chait, B. T., Improved beta-elimination-based affinity purification strategy for enrichment of phosphopeptides. Anal Chem. 2003, 75, 6826-6836.
86. Pierce, M. W., Palmer, J. L., Keutmann, H. T., Hall, T. A., Avruch, J., The insulin-directed phosphorylation site on ATP-citrate lyase is identical with the site phosphorylated by the cAMP-dependent protein kinase in vitro. J. Biol. Chem. 1982, 257, 10681-10686.
87. Salih, E., Phosphoproteomics by mass spectrometry and classical protein chemistry approaches. Mass Spectrom. Rev. 2005, 24, 828-846.
88. Loyet, K. M., Stults, J. T., Arnott, D., Mass spectrometric contributions to the practice of phosphorylation site mapping through 2003: A literature review. Mol. Cell. Proteomics 2005, 4, 235-245.
89. Reinders, J., Sickmann, A., State-of-the-art in phosphoproteomics. Proteomics 2005, 5, 4052-4061.
90. Goshe, M. B., Characterizing phosphoproteins and phosphoproteomes using mass spectrometry. Brief Funct. Genomic Proteomic 2006, 4, 363-376.
91. Pinkse, M. W., Uitto, R M., Hilhorst, M. J., Ooms, B., Heck, A. J., Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLCESI-MS/MS and titanium oxide precolumns. Anal Chem. 2004, 76, 3935-3943.
92. Wolschin, F., Wienkoop, S., Weckwerth, W., Enrichment of phosphorylated proteins and peptides from complex mixtures using metal oxide/hydroxide affinity chromatography (MOAC). Proteomics 2005, 5, 4389-4397.
93. Metodiev, M. V., Timanova, A., Stone, D. E., Differential phosphoproteome profiling by affinity capture and tandem matrix-assisted laser desorption/ionization mass spectrometry. Proteomics 2004, 4, 1433-1438.
94. Sweet, S. M., Cooper, H. J., Electron capture dissociation in the analysis of protein phosphorylation. Expert Rev. Proteomics 2007, 4, 149-159.
95. Gruhler, A. et al., Quantitative phosphoproteomics applied to the yeast pheromone signaling pathway. Mol. Cell. Proteomics 2005, 4, 310-327.
96. Kopf, E., Shnitzer, D., Zharhary, D., Panorama Ab microarray cell signaling kit: A unique tool for protein expression analysis. Proteomics 2005, 5, 2412-2416.
97. Akkiprik, M., Nicorici, D., Cogdell, D., Jia, Y. J. et al., Dissection of signalling pathways in fourteen breast cancer cell lines using reverse phase protein lysate microarrays. Technol. Cancer Res. Treat. 2006, 5, 543-551.
98. Cowherd, S. M., Espina,V. A., Petricoin, E. F., Loitta, L. A., Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse phase microarrays. Clin. Breast Cancer 2004, 5, 385-392.
99. Liang, X., Zhao, J., Hajivandi, M., Wu, R. et al., Quantification of membrane and membrane bound proteins in normal and malignant breast cancer cells isolated from the Same Patient with primary Breast Carcinoma. J. Proteome Res. 2006, 5, 2632-2641.
100. Canelle, L., Bousequet, J., Pionneau, C., Hardouin, J., A proteomic approach to investigate potential biomarkers directed against membrane-associated breast cancer proteins. Electrophoresis 2006, 27, 1609-1616.
101. Xiang, R., Dillon, D. A., Negin, B., Horvath, C., Wilkins, J. A., 2DLC/ MS analysis of membrane proteins from breast cancer cell-lines MCF7 and BT474. J. Proteome Res. 2004, 3, 1278-1283.
102. Jung, E. J., Moon, H. G., Cho, B. I., Jeong, C. Y. et al., Galectin-1 expression in cancer-associated stromal cells correlates tumour invasiveness and tumour progression in breast cancer. Int. J. Cancer. 2007, 120, 2331-2338.
103. Shin, B. K., Wang, H., Hanash, S., Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J. Mammary Gland Biol. Neoplasia 2002, 7, 407-413.
104. Davis, M. A., Hanash, S., High throughput genomic technology in research and clinical management of breast cancer. Plasma based proteomics in early detection and therapy. Breast Cancer Res. 2006, 8, 217.
105. Celis, J. E., Moreira, J. M. A., Gromova, I., Cabezon, T. et al., Towards discovery driven translational research in breast cancer. FEBS J. 2005, 272, 2-15.
106. Nevalainen, M. T., Xie, J., Torhorst, J., Bubendorf, L. et al., Signal Transducer and activator of transcription-5 activation and breast cancer prognosis. J. Clin. Oncol. 2004, 22, 2053-2060.
107. Rapkiewicz, A., Espina, V., Zujewski, J. A., Lebowitz, P. F. et al., The needle in the haystack: Application of breast fine needle aspirate samples to quantitative protein microarray technology. Cancer 2007, 25, 173-184.
108. Malkas, L. H., Herbert, B. S., Abdel-Aziz, W., Dobrolecki, L. E. et al., A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. PNAS 2006, 103, 19472-19477.
109. Ferguson, A. T., Evron, E., Umbricht, C. B., Pandita, T. K. et al., High frequency pf hypermethylation at the 14-3-3 sigma locus leads to gene silencing in Breast cancer cells. PNAS 2001, 97, 6049-6054.
110. Vercoutter-Edouart, A. S., Lemoine, J., Le Bourhis, X. L. et al., Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells. Cancer Res. 2001, 61, 76-80,
111. Hermaking, H., Lengauer, C., Polyak, K., He, T. C. et al., 14-3-3 sigma is a p53 regulatoed inhibitor of G2/M progression. Mol. Cell 997, 1, 3-11.
112. Fu, H., Subramanian, R. R., Masters, S. C., 14-3-3 proteins: Structure, function and regulation. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 617-647.
113. Souchelnytskiy, S., Proteomics of TGF-Beta signalling and its impact on breast cancer. Future Drugs 2005, 2, 925-935.
114. Soskic, V., Gorlach, M., Poznanovic, S., Boehmer, F. D. et al., Functional proteomic analysis of signal transduction pathways of platelet derived growth factor beta receptor. Biochemistry 1999, 38, 1757-1764.
115. Pandey, A., Podtelejnikov, A. V., Blagoev, B., Bustelo, X. R. et al., Analysis of receptor signalling pathways by mass spectroscopy: Identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors. PNAS 2000, 97, 179-184.
116. Hinsby, A. M., Olsen, J. V., Mann, M., Tyrosine phosphproteomics of FGF signalling- a role for insulin receptor substrate-4. J. Biol. Chem. 2004, 279, 46438.
117. Zhang, Y., Alejandro, W.-Y., Ross, P. L., Pappin, D. J. et al., Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signalling network reveals dynamic modules. Mol. Cell. Proteomics 2005, 4, 1240-1250.
118. Nielson, U. B., Gardone, M. H., Sirskey, A. J., McBeath, G., Soorger, P. K., Profiling receptor tyrosine kinase activation by using antibody microarrays. PNAS 2003, 100, 9330-9335.
119. Campbell, M. J., Esserman, L. J., Zhou, Y., Shoemaker, M. et al., Breast cancer growth prevention studies. Cancer Res. 2006, 66, 8707-8714.
120. Crugliano, T., Quaresima, B., Gaspari, M., Faniello, M. C. et al., Specific changes in the proteome pattern produced by the BRCA-1Ser1841Asn missense mutation. Int. J. Biochem. Cell Biol. 2007, 39, 220-226.
121. Boutros, R., Fanayan, S., Shehata, M., Byrne, J. A., The tumour protein D52 family: Many pieces, many puzzles. Biochem. Biophys. Res. Commun. 2004, 325, 1115-1121.
122. Tashiro, K., Konishi, H., Sano, E., Nabeshi, H. et al., Suppression of the ligand-mediated down regulation of epidermal growth factor receptor by Ymer, a novel tyrosine-phosphorylated and ubiquitinated protein. J. Biol. Chem. 2006, 281, 24612-24622.
123. Rose, R., Henrik, M., Scott-Patterson, A., Bitok, J. K. et al., Phosphoproteomic analysis HER2/neu signalling and inhibition. PNAS 2006, 103, 9773-9778.
124. Vandermoere, F., Yazidi-Belkoura, I. E., Demon, Y., Slomainny, C. et al., Proteomics exploration reveals that actin is a signalling target of the kinase Akt. Mol. Cell. Proteomics 2007, 6, 114-124.
125. Amanchy, R., Kalume, D. E., Iwahori, A., Zhong, J., Pandey, A., Phosphoproteome analysis of HELA cells using stable isotope labeling with amino acids in cell culture (SILAC). J. Proteome Res. 2005, 4, 1661-1671.
126. Chuthapisith, S., Layfield, R., Kerr, I. D., Hughes, C., Eremin, O., Proteomic profiling of MCF7 breast cancer cells with chemoresistence to different types of anticancer drugs. Int, J. Oncol. 20071, 30, 1545-1551.
127. Manjili, M. H., Arnouk, H., Knutson, K. L., Kmieciak, M. et al., Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res. Treat. 2006, 96, 243.
128. Somiari, R. I., Somiari, S., Russel, S., Shriver, C. D., Proteomics of breast carcinomas. J. Chromatogr. Analyt. Technol. Biomed. Life Sci. 2005, 815, 215-225.